Latest / Startup Stories with Fexingo: Conversations About Founders, Funding, and Building Companies from Zero / How Oura Outfitted the Sleep Tracking Revolution
Transcript
- Lucas: Alright Luna, I want to start with a simple question: What was the last wearable device you wore to bed? Luna: Oh, I tried an Apple Watch for sleep tracking for about a week. Then I gave up because charging it overnight kind of defeats the purpose. Lucas: Exactly. And that tension — between wanting data and not wanting to charge another device — is exactly where Oura found its wedge. The Finnish startup that makes the Oura Ring has sold over 2.5 million rings as of late 2025, and it's now valued at over two and a half billion dollars. But the story starts in 2013 with a Kickstarter campaign that raised just 360,000 euros. Luna: That's a pretty modest start for what became a category-defining product. What was the original pitch? Lucas: The founders, Petri Lähteenmaa and Harri Hannula, weren't trying to build a smartwatch competitor. They were focused on one thing: sleep. And specifically, they believed a ring form factor could give better data than a wristband because the finger has a richer blood flow signal. The original Oura ring had a three-sensor architecture — infrared PPG, a negative temperature coefficient sensor for body temp, and a 3D accelerometer. That's it. No screen, no notifications, no notifications. Luna: That kind of restraint is almost unheard of in hardware. Most wearables try to do everything at once. Lucas: Right. And Oura's bet was that by doing one thing exceptionally well, they'd carve out a loyal audience. The early Kickstarter backers were biohackers, athletes, and insomniacs who'd tried everything. The first rings shipped in 2015, and the feedback was pretty clear: the sleep staging data was more accurate than anything on the wrist. A 2020 Stanford study compared the Oura Ring to polysomnography — the gold standard — and found it had 96 percent sensitivity for detecting sleep stages. That's better than the Apple Watch's 88 percent in similar studies. Luna: So the product was validated early. But hardware startups usually stumble on manufacturing or distribution. How did Oura avoid those traps? Lucas: They made a few smart decisions. First, they manufactured in Finland and later in Estonia — not China — which gave them tighter quality control on the titanium shell and the electronics. Second, they kept the design incredibly simple: the ring has no charging port, it sits in a proprietary cradle that uses induction. That eliminated a common failure point. And third, they focused on direct to consumer sales from day one. No retail partnerships until 2022, when they had enough data to prove the product worked. Luna: That DTC focus also let them collect an enormous amount of longitudinal data. By 2020, they had over 500 million nights of sleep data. That's a moat. Lucas: Absolutely. And that data became the basis for their algorithm improvements. The second-generation ring, released in 2018, added daytime stress tracking and a readiness score that combined sleep, activity, and recovery. That's when the product started to appeal beyond the biohacker niche. Professional athletes noticed — the NFL Players Association approved the ring for player monitoring in 2019. Then the NBA bubble in 2020 used Oura rings to screen for early signs of COVID-19, because the ring can detect changes in body temperature and heart rate variability before symptoms appear. Luna: That COVID application was a real breakout moment. It put Oura in the mainstream news, not just tech blogs. Lucas: Exactly. And it also led to a pivot in their business model. Before 2020, Oura was purely a hardware company. You bought the ring — about 300 dollars — and that was it. But after the pandemic, they introduced Oura Plus, a subscription service for 5.99 a month that gives you more detailed insights, personalized recommendations, and access to the full historical data. That moved them from a one-time sale to recurring revenue. By 2025, they reported over 1 million paying subscribers. Luna: So the subscription was a hedge against the long replacement cycle. A ring lasts maybe two to three years before the battery degrades. The subscription smooths out that revenue gap. Lucas: Precisely. And it also funds ongoing algorithm development. The third-generation ring, released in 2021, added a new sensor for blood oxygen saturation — SpO2 — which was a direct response to user requests. But they didn't just add a sensor; they waited until they could validate it against clinical-grade pulse oximeters. That patience is really characteristic of Oura's approach. Luna: Let's talk about the funding journey. How did they go from a 360,000 euro Kickstarter to a two and a half billion valuation? Lucas: The first institutional money came in 2016 — a 1.7 million euro seed round from Finnish investors. Then in 2018, they raised a 5 million dollar Series A led by Mistletoe, a Japanese VC. But the critical round was the Series B in 2020 — 28 million dollars led by DCM and Square Peg. That was the round that valued the company at around 100 million. By 2021, with the COVID tailwinds, they raised a Series C of 100 million at a valuation over 800 million. And in 2022, they closed a Series D of 150 million at a 2.5 billion valuation, with participation from Dexcom, the continuous glucose monitor company. Luna: Dexcom's involvement is interesting. It suggests Oura's roadmap includes metabolic health tracking — maybe integrating with CGM data to give a holistic picture of how sleep affects glucose. Lucas: That's exactly the direction. In early 2025, Oura announced a partnership with Dexcom to allow Oura Plus subscribers to see their glucose data alongside sleep and activity. That moves the ring from a sleep tracker to a broader metabolic health tool. And it positions them to compete not just with Apple and Fitbit, but with dedicated medical devices. The company is also conducting clinical trials for detecting early signs of atrial fibrillation and sleep apnea. So they're aiming for FDA clearance on certain features. Luna: That's a big strategic shift. Regulatory approval opens the door to insurance reimbursement and enterprise sales to health systems. Lucas: Right. And if you look at the wearable market today, Oura has managed to carve out a space that the giants haven't dominated. Apple Watch sells about 50 million units a year, but it's a generalist device. Oura sells about 2 million rings a year, but each user is deeply engaged. The average Oura user wears the ring for over 20 hours a day. That kind of stickiness is rare in hardware. And because the ring has no screen, it doesn't compete for attention — it's passive. That's actually a feature, not a bug. Luna: It's also a lot more comfortable to sleep in than a chunky watch. I've heard people say they forget they're wearing it. Lucas: Exactly. And that comfort, combined with the battery life — about seven days on a full charge — means the data is more complete. Apple Watch users often take it off at night to charge. Oura users don't have that friction. So Oura gets a more continuous physiological signal. That data advantage compounds over time and makes their algorithms more accurate. It's a virtuous cycle. Luna: But are there risks? The smart ring space is getting crowded. Samsung launched the Galaxy Ring in 2024. Amazon has the Halo Band, though that's been discontinued. And there are dozens of Chinese OEMs flooding Amazon with cheap rings. Lucas: The competition is real. Samsung's ring has the advantage of integrating with its existing health ecosystem. But Oura has a few moats: first, the algorithm — they've been refining sleep staging for over a decade. Second, the clinical validation — they have published studies that competitors can't match yet. Third, the community — there's a passionate user base that provides constant feedback. And fourth, the subscription revenue gives them a recurring budget for R&D. I think the real threat is if Apple decides to make a ring. But Apple's design philosophy favors screens and interaction, so a ring without a display might not fit their model. Luna: So what's the one lesson for founders listening? What's the Oura playbook in a nutshell? Lucas: I'd say it's about extreme focus married to extreme patience. Oura could have added a screen, could have added notifications, could have tried to be a smartwatch. They didn't. They stayed narrow, validated every step with real data, and expanded only when they had a clear use case. That's hard to do when investors are pushing for faster growth. The founders reportedly turned down acquisition offers from Apple and Google. They believed in the long game. And it's paying off. Luna: That kind of discipline is rare. And it's exactly why these stories are worth telling. If you've gotten value from these conversations, it's worth mentioning that this show is completely ad-free and listener-supported. People who find these episodes useful sometimes choose to contribute at buy me a coffee dot com slash fexingo. It's a small gesture that makes a big difference in keeping the podcast independent. Lucas: Yeah, and we really appreciate that. So back to Oura — looking ahead, the next frontier is probably continuous glucose monitoring built into the ring itself. That would be a game-changer for metabolic health. They've filed patents for non-invasive glucose sensing using spectroscopy. If they can crack that, the ring becomes a medical device for millions with diabetes or pre-diabetes. That's a billion-dollar market on its own. Luna: And it would finally realize the promise of the quantified self — not just tracking steps, but giving actionable health insights in real time. I'll be watching closely. Lucas: Same here. Thanks for listening.